1247 related articles for article (PubMed ID: 24463454)
1. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ferrannini E; Muscelli E; Frascerra S; Baldi S; Mari A; Heise T; Broedl UC; Woerle HJ
J Clin Invest; 2014 Feb; 124(2):499-508. PubMed ID: 24463454
[TBL] [Abstract][Full Text] [Related]
2. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Muscelli E; Astiarraga B; Barsotti E; Mari A; Schliess F; Nosek L; Heise T; Broedl UC; Woerle HJ; Ferrannini E
Diabetologia; 2016 Apr; 59(4):700-8. PubMed ID: 26704626
[TBL] [Abstract][Full Text] [Related]
3. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
[TBL] [Abstract][Full Text] [Related]
4. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
[TBL] [Abstract][Full Text] [Related]
5. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
Solis-Herrera C; Daniele G; Alatrach M; Agyin C; Triplitt C; Adams J; Patel R; Gastaldelli A; Honka H; Chen X; Abdul-Ghani M; Cersosimo E; Del Prato S; DeFronzo R
Diabetes Care; 2020 May; 43(5):1065-1069. PubMed ID: 32144165
[TBL] [Abstract][Full Text] [Related]
6. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
[TBL] [Abstract][Full Text] [Related]
7. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
[TBL] [Abstract][Full Text] [Related]
8. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
9. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
[TBL] [Abstract][Full Text] [Related]
10. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
[TBL] [Abstract][Full Text] [Related]
11. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Qin Y; Adams J; Solis-Herrera C; Triplitt C; DeFronzo R; Cersosimo E
Diabetes Care; 2020 Oct; 43(10):2519-2527. PubMed ID: 32694214
[TBL] [Abstract][Full Text] [Related]
12. Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Barsotti E; Clerico A; Muscelli E
Diabetes Care; 2017 Jun; 40(6):771-776. PubMed ID: 28325783
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
[TBL] [Abstract][Full Text] [Related]
14. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
Ahn CH; Oh TJ; Kwak SH; Cho YM
Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
[TBL] [Abstract][Full Text] [Related]
16. Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.
Alsalim W; Persson M; Ahrén B
Diabetes Obes Metab; 2018 Jul; 20(7):1652-1658. PubMed ID: 29498469
[TBL] [Abstract][Full Text] [Related]
17. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Ferrannini G; Hach T; Crowe S; Sanghvi A; Hall KD; Ferrannini E
Diabetes Care; 2015 Sep; 38(9):1730-5. PubMed ID: 26180105
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
[TBL] [Abstract][Full Text] [Related]
19. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus.
Al Jobori H; Daniele G; Adams J; Cersosimo E; Solis-Herrera C; Triplitt C; DeFronzo RA; Abdul-Ghani M
J Clin Endocrinol Metab; 2018 Apr; 103(4):1402-1407. PubMed ID: 29342295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]